[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100615383":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":29,"centralContacts":34,"locations":40,"responsibleParty":53,"collaborators":25,"id":55,"slug":25,"hasResults":56,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":25,"eligibilityCriteria":60,"healthyVolunteers":56,"sex":61,"minAge":62,"maxAge":25,"enrollmentInfo":63,"targetDuration":25,"studyType":66,"phases":67,"briefSummary":69,"conditions":70,"keywords":25,"overallStatus":72,"whyStopped":25,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":82},{"fullName":5,"class":6},"British Columbia Cancer Agency","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"High-Dose RT","EXPERIMENTAL","27Gy in 3 fractions with boost",[13],"Radiation: Palliative Radiotherapy",{"label":15,"type":16,"description":17,"interventionNames":18},"Standard Dose Palliative RT","ACTIVE_COMPARATOR","24Gy in 3 fractions",[13],[20,26],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"RADIATION","Palliative Radiotherapy","standard dose RT",[15],null,{"type":21,"name":22,"description":27,"armGroupLabels":28,"otherNames":25},"high-dose RT",[9],[30],{"name":31,"affiliation":32,"role":33},"Wei Liu, MD, FRCPC","BC Cancer - Vancouver","PRINCIPAL_INVESTIGATOR",[35],{"name":36,"role":37,"phone":38,"phoneExt":25,"email":39},"Sandy Chang","CONTACT","6048776000","sandy.chang@bccancer.bc.ca",[41],{"facility":32,"status":25,"city":42,"state":43,"zip":25,"country":44,"cosmosGeoPoint":45,"geoPoint":50,"contacts":51},"Vancouver","British Columbia","Canada",{"type":46,"coordinates":47},"Point",[48,49],-123.11934,49.24966,{"lat":49,"lon":48},[52],{"name":36,"role":37,"phone":38,"phoneExt":25,"email":39},{"type":54,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR","100615383",false,"NCT07291895","High Dose Radiotherapy for Palliation (Hi-D)","A Prospective Single-blinded Randomized Study of High Dose Radiotherapy for Palliation: Hi-D","Inclusion Criteria:\n\n* Subjects must meet all the following criteria to be eligible for participation in this study:\n* Age 18 or older.\n* Able to provide informed consent\n* Patient has histologically confirmed solid tumour malignancy\n* ECOG performance status 0 - 2\n* Life Expectancy \\> 6 months\n* 1-5 target lesions larger than 5cm\n* A history and physical exam, including ECOG performance status, performed within 6 weeks prior to trial enrollment\n* Not suitable for or declined curative-intent treatment\n* Subject has had a CT neck, chest, abdomen and pelvis or PET-CT within 8 weeks prior to enrollment, and with 12 weeks of treatment\n* MRI spine for patients receiving RT to vertebral or paraspinal metastases\n* Patient is judged able to:\n\n  * Maintain a stable position during therapy\n  * Tolerate immobilization device(s) that may be required to deliver radiation safely\n\nExclusion Criteria:\n\n* \\- Hematologic malignancy.\n* Disease limited to intracranial sites\n* Serious medical co-morbidities precluding radiotherapy\n* Bone metastases with no soft tissue component\n* Prior radiation to target lesion that precludes delivery of repeat radiation. All such cases should be discussed with the local and study PIs.\n* Pregnant women","ALL","18 Years",{"count":64,"type":65},20,"ESTIMATED","INTERVENTIONAL",[68],"NA","The goal of this clinical trial is to evaluate the feasibility of single-blind randomization between two palliative regimens - standard 24 Gray in 3 fractions vs a high-dose (Hi-D) 27 Gray in 3 fractions with dose escalation within the tumor in participants with bulky metastatic cancer.\n\nThe main question",[71,22],"Metastases","NOT_YET_RECRUITING","2025-12-05",{"date":75,"type":76},"2025-12-18","ACTUAL",{"date":78,"type":65},"2026-01-01",{"date":80,"type":65},"2029-08-31",{"name":5,"class":6},1]